Drug intelligence / Profile preview

Guizhi Boosting Decoction

Development stage: Preclinical
Lead developer: Xiyuan Hospital
Administration: Oral

Overview

Guizhi Boosting Decoction is a traditional Chinese medicine herbal formulation. It is currently being investigated in clinical trials for the treatment of primary hypotension, specifically targeting cases associated with Heart Qi Deficiency Syndrome. The decoction is also being explored for its potential to improve cardiopulmonary exercise tolerance and address atherosclerosis, suggesting a broader therapeutic scope within traditional Chinese medicine principles.

Targets

IL1B (Interleukin-1 beta)IL-6 (Interleukin 6)MAPK14 (p38 mitogen-activated protein kinase alpha)MAPK3 (Mitogen-activated protein kinase 1)MMP2 (Matrix metalloproteinase-2)MMP9 (Matrix metalloproteinase-9)NFKB1 (NF-κB1)RAF1 (c-Raf-1 (Y340D/Y341D))STAT3 (Signal Transducer and Activator of Transcription 3)TP53 (Cellular Tumor Antigen p53 R175H)

Beyond the preview

Go deeper on Guizhi Boosting Decoction.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guizhi Boosting Decoction.